URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Daniel Shinyu Chen net worth and biography

Daniel Chen Biography and Net Worth

Insider of IGM Biosciences

Daniel Chen, M.D., Ph.D. has served as our Chief Medical Officer since August 2018. Prior to joining us, Dr. Chen served in various positions at Roche/Genentech, a biopharmaceutical company, starting in 2006, including most recently as Vice President, Global Head of Cancer Immunotherapy from May 2016 to July 2018. While at Roche/Genentech, Dr. Chen also served as Cancer Immunotherapy Franchise Head, Product Development from 2014 to 2018 and led the development of Tecentriq from entry into first in human studies to multiple global registration approvals. Dr. Chen was elected to the board of directors of the Society for Immunotherapy of Cancer in July 2018. Dr. Chen received a B.S. in Life Sciences from the Massachusetts Institute of Technology and an M.D. and Ph.D. from the University of Southern California, Keck School of Medicine and Microbiology. He completed his residency in internal medicine, a fellowship in Medical Oncology and a Post-doctorate in Immunology at Stanford University. Dr. Chen also ran the metastatic melanoma clinic at the Stanford Cancer Center from 2003 to 2006, where he studied human immune responses to cancer vaccination and cytokine administration and continued to care for melanoma patients until 2016.

What is Daniel Shinyu Chen's net worth?: The estimated net worth of Daniel Shinyu Chen is at least $803,974.20 as of May 26th, 2021. Dr. Chen owns 116,518 shares of IGM Biosciences stock worth more than $803,974 as of December 21st. This net worth estimate does not reflect any other assets that Dr. Chen may own. Learn More about Daniel Shinyu Chen's net worth.
How do I contact Daniel Shinyu Chen?: The corporate mailing address for Dr. Chen and other IGM Biosciences executives is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. IGM Biosciences can also be reached via phone at 650-965-7873. Learn More on Daniel Shinyu Chen's contact information.
Has Daniel Shinyu Chen been buying or selling shares of IGM Biosciences?: Daniel Shinyu Chen has not been actively trading shares of IGM Biosciences during the past quarter. Most recently, Daniel Shinyu Chen sold 444 shares of the business's stock in a transaction on Wednesday, May 26th. The shares were sold at an average price of $70.00, for a transaction totalling $31,080.00. Following the completion of the sale, the insider now directly owns 116,518 shares of the company's stock, valued at $8,156,260. Learn More on Daniel Shinyu Chen's trading history.
Who are IGM Biosciences' active insiders?: IGM Biosciences' insider roster includes Daniel Chen (Insider), Julie Hambleton (Director), and Bruce Keyt (Insider). Learn More on IGM Biosciences' active insiders.
Are insiders buying or selling shares of IGM Biosciences?: During the last twelve months, IGM Biosciences insiders bought shares 2 times. They purchased a total of 367,473 shares worth more than $3,167,890.26. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 37,701 shares worth more than $424,907.54. The most recent insider tranaction occured on December, 16th when insider Steven Weber sold 539 shares worth more than $4,031.72. Insiders at IGM Biosciences own 57.0% of the company. Learn More about insider trades at IGM Biosciences.
Information on this page was last updated on 12/16/2024.

Daniel Shinyu Chen Insider Trading History at IGM Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/26/2021	Sell	444	$70.00	$31,080.00	116,518
12/8/2020	Sell	1,219	$91.00	$110,929.00	118,373
12/2/2020	Sell	608	$63.15	$38,395.20	117,423
11/4/2020	Sell	605	$50.00	$30,250.00	117,468
10/2/2020	Sell	1,830	$73.50	$134,505.00	119,368
9/18/2020	Sell	609	$77.91	$47,447.19	117,468
9/8/2020	Sell	602	$50.20	$30,220.40	116,518
8/27/2020	Sell	605	$45.13	$27,303.65	116,518

Daniel Shinyu Chen Buying and Selling Activity at IGM Biosciences

IGM Biosciences Company Overview

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Today's Range

Now: $6.90

$6.76

$7.50

50 Day Range

MA: $12.06

$6.90

$17.83

2 Week Range

Now: $6.90

$6.17

$22.50

Volume

434,862 shs

Average Volume

301,638 shs

Market Capitalization

$410.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08